Goldline Pharmaceutical Ltd to Consider H1 FY27 Results Nov 14

Goldline Pharmaceutical Ltd will consider its standalone unaudited financial results for the half-year ended September 30, 2026, at a board meeting on November 14, 2026, following a 45.3% rise in FY26 net profit to ₹4.12 crore. The disclosure is significant because it will provide the first reported financial update for GLPL after its March 2026 annual results.

When will GLPL consider its H1 FY27 results?

GLPL's Board of Directors is scheduled to meet on Saturday, November 14, 2026, to consider and approve standalone unaudited financial results for the half-year ended September 30, 2026. The company made the board-meeting disclosure to BSE on November 5 under Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The meeting is to be held at GLPL's registered office in Nagpur, Maharashtra. Along with the half-yearly financial statements, the board is scheduled to consider a statement of assets and liabilities. The available filing does not contain the September 2026 sales, profit, margin or balance-sheet figures, since these are to be considered at the meeting.

GLPL had also stated that its insider-trading compliance window would close from October 1, 2026, ahead of the reporting process for the September-ended period. The company said the unaudited results would be disclosed separately and made available on its website.

What did GLPL report in its latest available financial results?

GLPL last reported results for the period ended March 2026, when sales were ₹17.31 crore and standalone net profit was ₹2.76 crore. This compared with sales of ₹13.89 crore and net profit of ₹1.36 crore in September 2025, according to the company's half-yearly results snapshot.

Operating profit before depreciation, interest and tax, excluding other income, was ₹4.31 crore in March 2026, against ₹2.64 crore in September 2025. Over the same comparison, the operating profit margin, excluding other income, increased to 24.90% from 19.01%, while interest expense declined slightly to ₹0.65 crore from ₹0.67 crore.

The following table summarises the disclosed financial figures. All revenue and profit amounts are presented in ₹ crore for consistency.

How did GLPL perform in FY26?

GLPL reported FY26 revenue from operations and other income of ₹31.20 crore, up 11.2% from ₹28.06 crore in FY25. Profit after tax increased 45.3% to ₹4.12 crore from ₹2.83 crore, based on the financial highlights presented at the company's 22nd annual general meeting on August 29, 2026.

Profit before tax rose 39.6% to ₹5.39 crore in FY26 from ₹3.86 crore a year earlier. Earnings per share improved to ₹5.97 from ₹4.11. The company attributed the higher profit margin in its full-year results to increased revenue, with the FY26 profit margin reported at 13%, compared with 10% in FY25.

The FY26 results were approved at a board meeting held on June 9, 2026, for the half-year and year ended March 31, 2026. The November 14 meeting is therefore the next scheduled financial-results event disclosed by the company.

What should investors assess in GLPL's November disclosure?

GLPL's November disclosure will show whether the improvement in sales, operating profit and net profit seen in the March 2026 results continued through the half-year ended September 2026. The announced agenda covers standalone unaudited results and a statement of assets and liabilities, making both earnings and balance-sheet information relevant to the update.

The disclosed data shows that profit expanded faster than sales in FY26 and in the March 2026 comparison with September 2025. However, no September 2026 financial figures, guidance, share-price movement or management outlook were included in the board-meeting intimation. Investors therefore have no disclosed basis yet to assess the half-year's revenue growth, profitability or cash and debt position.

For the broader market, the immediate significance is the timing of a formal financial update from a listed pharmaceutical company. The filing is a compliance-based intimation rather than an earnings announcement, and the outcome of the board meeting will determine the financial data available for assessment.

Conclusion

GLPL is scheduled to consider standalone unaudited H1 FY27 results on November 14, 2026, after reporting stronger FY26 profitability. Its FY26 profit after tax rose 45.3% to ₹4.12 crore, while the March 2026 results snapshot showed sales of ₹17.31 crore and standalone net profit of ₹2.76 crore.

The next item to watch is the board-meeting outcome, including the September 2026 half-yearly results and statement of assets and liabilities. These disclosures will provide the first confirmed figures for GLPL's financial performance after March 2026.